Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $8.00 | Buy | Guggenheim |
| 8/28/2024 | $10.00 | Buy | ROTH MKM |
| 11/27/2023 | $35.00 | Buy | H.C. Wainwright |
| 9/12/2023 | $40.00 | Buy | Maxim Group |
| 2/15/2023 | $10.00 | Speculative Buy | The Benchmark Company |
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were
Benchmark analyst Bruce Jackson reiterates Genelux (NASDAQ:GNLX) with a Speculative Buy and maintains $25 price target.
Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.75, a high estimate of $32.00, and a low estimate of $25.00. This current average represents a 8.46% decrease from the previous
Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were
Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the addition of industry veterans John Smither and Jim Williams, MBA, as Senior Advisors. "John and Jim are seasoned veterans in the field, and each brings a differentiated skill set that will enable us to strengthen our execution across the private and public investment strategies of the firm," said Patrick Heron, Managing Partner at FLS. John has over 25 years of financial experience in the biopharmaceutical industry. Before joining FLS, John served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc., where he led the company's successful initial public offering
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small cell lung cancer (NSCLC) with Olvi-Vec, followed by platinum-doublet chemotherapy + immune checkpoint inhibitor. Additionally, a Phase 1b/2 lung cancer trial is ongoing in recurrent small cell lung cancer (SCLC) in China which is co-sponsored with Newsoara BioPharma Co., Ltd. Both trials
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer – – Trial represents second indication in the clinic for Olvi-Vec via systemic administration – – Interim readout expected mid-2025 – WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC)
4 - GENELUX Corp (0001231457) (Issuer)
4/A - GENELUX Corp (0001231457) (Issuer)
4 - GENELUX Corp (0001231457) (Issuer)
Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00
ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00
H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00
SC 13G - GENELUX Corp (0001231457) (Subject)
SC 13G/A - GENELUX Corp (0001231457) (Subject)
SC 13G - GENELUX Corp (0001231457) (Subject)
10-Q - GENELUX Corp (0001231457) (Filer)
8-K - GENELUX Corp (0001231457) (Filer)
10-Q - GENELUX Corp (0001231457) (Filer)